152 related articles for article (PubMed ID: 38065887)
1. Effect of dynamic platelet-to-lymphocyte ratio on the prognosis of patients with esophageal squamous cell carcinoma receiving chemoradiotherapy.
He D; Du S; He S; Song H; Pu B; Zhang G; Yang C
Medicine (Baltimore); 2023 Dec; 102(49):e36554. PubMed ID: 38065887
[TBL] [Abstract][Full Text] [Related]
2. [Study on the prognostic influencing factors of esophageal squamous cell carcinoma and the predictive value of inflammatory reaction indexes on its postoperative recurrence].
Wang X; Wang Z; Lu WL; Zhao GF
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):160-164. PubMed ID: 36781237
[No Abstract] [Full Text] [Related]
3. Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer.
Xie X; Luo KJ; Hu Y; Wang JY; Chen J
Dis Esophagus; 2016 Jan; 29(1):79-85. PubMed ID: 25410116
[TBL] [Abstract][Full Text] [Related]
4. The prognostic role of pre-treatment neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy.
Man Q; Li P; Fan J; Yang S; Xing C; Bai Y; Hu M; Wang B; Zhang K
BMC Cancer; 2024 Apr; 24(1):464. PubMed ID: 38616289
[TBL] [Abstract][Full Text] [Related]
5. Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma.
Yang Y; Tan H; Lu Y; Mei J; Zhang M; Bai M; Wang X; Ge S; Ning T; Zhang L; Ji Z; Duan J; Sun Y; Wang F; Liu R; Li H; Deng T
BMC Cancer; 2024 Feb; 24(1):249. PubMed ID: 38389042
[TBL] [Abstract][Full Text] [Related]
6. A nomogram to predict short-term outcome of radiotherapy or chemoradiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma.
Liang S; Li C; Gao Z; Li J; Zhao H; Yu J; Meng X
Int Immunopharmacol; 2021 Jan; 90():107178. PubMed ID: 33218939
[TBL] [Abstract][Full Text] [Related]
7. Elevated Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio after First Cycle of Chemotherapy and Better Survival in Esophageal Cancer Patients Receiving Concurrent Chemoradiotherapy.
Tseng RH; Lai KM; Tsai CY; Yan SL
Curr Oncol; 2022 Nov; 29(11):8825-8834. PubMed ID: 36421347
[No Abstract] [Full Text] [Related]
8. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma.
Feng JF; Huang Y; Chen QX
World J Surg Oncol; 2014 Mar; 12():58. PubMed ID: 24641770
[TBL] [Abstract][Full Text] [Related]
9. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
Yılmaz U; Ozdemir O; Batum O; Ermin S
Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
[TBL] [Abstract][Full Text] [Related]
10. The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study.
Toyokawa T; Kubo N; Tamura T; Sakurai K; Amano R; Tanaka H; Muguruma K; Yashiro M; Hirakawa K; Ohira M
BMC Cancer; 2016 Sep; 16(1):722. PubMed ID: 27599460
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of the systemic immune-inflammation index for predicting survival in esophageal squamous cell carcinoma after radical radiotherapy.
Wang Y; Lyu J; Jia H; Liang L; Xiao L; Liu Y; Liu X; Li K; Chen T; Zhang R; Zhang H; Tang C; Li T
Future Oncol; 2021 Jul; 17(20):2647-2657. PubMed ID: 34008415
[TBL] [Abstract][Full Text] [Related]
12. Impact of the Platelet-to-Lymphocyte Ratio as a Biomarker for Esophageal Squamous Cell Carcinoma.
Kato T; Oshikiri T; Goto H; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Kakeji Y
Anticancer Res; 2022 May; 42(5):2775-2782. PubMed ID: 35489759
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiation-induced changes in systemic inflammatory markers and their prognostic significance in oesophageal squamous cell carcinoma.
Khin NS; Tan SH; Wang ML; Siow TR; Lim FL; Wang FQ; Ng MC; Lam JY; Yip C
Br J Radiol; 2021 Jun; 94(1122):20200314. PubMed ID: 33861156
[TBL] [Abstract][Full Text] [Related]
14. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
15. Predictive values of the hemoglobin, albumin, lymphocyte and platelet score (HALP) and the modified -Gustave Roussy immune score for esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy.
Shi Y; Shen G; Zeng Y; Ju M; Chen X; He C; Liang L; Ge X; Sun X; Di X
Int Immunopharmacol; 2023 Oct; 123():110773. PubMed ID: 37562292
[TBL] [Abstract][Full Text] [Related]
16. Platelet to lymphocyte ratio is a predictive marker of prognosis and therapeutic effect of postoperative chemotherapy in non-metastatic esophageal squamous cell carcinoma.
Yang Y; Xu H; Zhou L; Deng T; Ning T; Liu R; Zhang L; Wang X; Ge S; Li H; Ba Y
Clin Chim Acta; 2018 Apr; 479():160-165. PubMed ID: 29325800
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
Qi WX; Wang X; Li C; Li S; Li H; Xu F; Chen J; Zhao S; Li H
Thorac Cancer; 2023 Jun; 14(17):1556-1566. PubMed ID: 37089116
[TBL] [Abstract][Full Text] [Related]
18. High Preoperative Platelet to Lymphocyte Ratio Is Associated with a Greater Risk of Postoperative Complications and Hematogenous Recurrences in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Treatment.
Sasahara M; Kanda M; Shimizu D; Takami H; Inokawa Y; Hattori N; Hayashi M; Tanaka C; Fujiwara M; Nakayama G; Kodera Y
Dig Surg; 2023; 40(1-2):48-57. PubMed ID: 36893749
[TBL] [Abstract][Full Text] [Related]
19. Systemic Immune-Inflammatory Index, Tumor-Infiltrating Lymphocytes, and Clinical Outcomes in Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy.
Yang J; Zheng J; Qiu J; Zhang M; Liu L; Wang Z; Zheng Q; Liu Y; Chen M; Li J
J Immunol Res; 2023; 2023():4275998. PubMed ID: 37228442
[TBL] [Abstract][Full Text] [Related]
20. The pretherapeutic systemic inflammation score is a prognostic predictor for elderly patients with oesophageal cancer: a case control study.
Huang C; Wang M; Chen L; Wang H; Huang D; Shi J; Zhang W; Tian Y; Zhu Y
BMC Cancer; 2023 Jun; 23(1):505. PubMed ID: 37270496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
